Acutely psychotic patients receiving high-dose haloperidol therapy

Area of Science:

• Psychiatry
• Pharmacology
• Clinical Neuroscience

Background:

• Current trends favor lower neuroleptic dosing for psychosis treatment.
• However, some patients receive higher-than-recommended doses of antipsychotics.
• Parenteral haloperidol is frequently used for acute psychosis management.

Purpose of the Study:

• To investigate the clinical outcomes and plasma haloperidol levels in acutely psychotic patients receiving regular versus high doses.
• To determine if higher haloperidol doses are justified by patient characteristics or drug levels.

Main Methods:

• Thirty-six acutely psychotic patients were divided into regular dose (RD: 10-30 mg) and high dose (HD: 40-80 mg) groups based on 24-hour parenteral haloperidol administration.
• Clinical assessments included the Brief Psychiatric Rating Scale (BPRS), Schedule for Affective Disorders and Schizophrenia-Change Version (SADS-C), and Nurses' Observation Scale for Inpatient Evaluation (NOSIE).
• Plasma haloperidol levels were measured and compared between groups.

Main Results:

• At baseline, patients in the HD group exhibited significantly higher scores on BPRS Hostile-Suspiciousness and NOSIE Irritability factors.
• Group assignment was not influenced by age, gender, weight, or illness duration.
• Plasma haloperidol levels did not justify the higher dosage in the HD group.

Conclusions:

• High-dose haloperidol administration in acute psychosis may be clinically inappropriate.
• Increased hostility and irritability at baseline in the high-dose group suggest potential over-treatment or misallocation of medication.
• Further research is needed to optimize neuroleptic dosing strategies for acute psychosis.